Type 2 diabetes is often accompanied by other comorbidities that similarly contribute to cardiovascular risk. New antidiabetics including glucagon-like peptide-1 agonists have demonstrated blood glucose control in patients with Type 2 diabetes with a low risk of hypoglycemia and a favorable impact on bodyweight. Evidence suggests that these agents may convey benefit in managing additional cardiovascular risks. In a recent pooled analysis of randomized controlled trial data, Okerson et al. identified a significant reduction in systolic blood pressure in patients treated with exenatide, particularly in patients with elevated systolic blood pressure. This study provides further evidence that glucagon-like peptide-1 agonists confer therapeutic benefit for managing Type 2 diabetes while also managing other cardiovascular risk factors.
- Dipeptidyl-peptidase-4 inhibitors
- Glucagon-like peptide-1 agonists
- Systolic blood pressure
- Type 2 diabetes
ASJC Scopus subject areas
- Internal Medicine
- Cardiology and Cardiovascular Medicine